Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
World Courier’s national operations manager in Canada covers the topics of moving to GxP standards, and the logistics challenges faced by being a logistics company in such a…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Mr. Pierre Laurin is a senior executive with 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic’s platform technology since 1989, Mr. Laurin…
You have had a wealth of experience in the pharmaceutical industry with different positions in key therapeutic areas, ranging from Argentina, Latin America, Middle East & Africa, Algeria, Switzerland and France.…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
With a Master’s Degree in Marketing Science from the University of Leicester and a Degree in Management Information Systems from Université du Québec à Montréal Jacques Dessurealt has had a…
Tell us about the Canada Foundation for Innovation (CFI) – where does Canada fit on the world stage of innovation and how are you ensuring Canada stands out as a…
Dr. Douville talks investment, the company’s role in R&D in Canada and their plans for some of their future products. You founded Milestone Pharmaceuticals in 2005, having founded Galileo Genomics…
See our Cookie Privacy Policy Here